Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design of Potent and Selective BCL6 Transcriptional Chemical Inducers of Proximity through Linker Optimization.

Journal of medicinal chemistry·2026
Same author

Driver mutations and tumor mutational burden impact stage IV melanoma survival.

Journal of the American Academy of Dermatology·2026
Same author

Use of ancillary studies in pediatric spitzoid neoplasms: A retrospective cohort study.

Journal of the American Academy of Dermatology·2026
Same author

Deuterated Pentoxifylline Analog in the Treatment of Necrobiosis Lipoidica: A Nonrandomized Clinical Trial.

JAMA dermatology·2026
Same author

Correction: Melanoma toolkit for early detection for primary care clinicians: a 1-year follow-up on outcomes.

Frontiers in medicine·2026
Same author

Expanding the conversation around radiotherapy for lentigo maligna: Response to "Radiotherapy versus imiquimod for complex lentigo maligna: A phase 3 randomized clinical trial".

Journal of the American Academy of Dermatology·2026

Related Experiment Video

Updated: Jun 7, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

The performance of MelaFind: a prospective multicenter study.

Gary Monheit1, Armand B Cognetta, Laura Ferris

  • 1Total Skin and Beauty Dermatology, Birmingham, Alabama, USA.

Archives of Dermatology
|October 20, 2010
PubMed
Summary

MelaFind, a computer-vision system, demonstrated high sensitivity (98.4%) in detecting early melanoma. This objective tool aids dermatologists, improving melanoma detection rates and reducing unnecessary biopsies.

Related Experiment Videos

Last Updated: Jun 7, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Area of Science:

  • Dermatology
  • Medical Imaging
  • Computer Vision

Background:

  • Early detection of cutaneous melanoma is crucial for patient survival.
  • Objective tools are needed to supplement clinical evaluation of pigmented skin lesions.
  • MelaFind is a noninvasive computer-vision system designed for melanoma detection.

Purpose of the Study:

  • To evaluate the safety and effectiveness of the MelaFind system.
  • To compare the diagnostic performance of MelaFind with that of dermatologists.
  • To assess MelaFind's utility in reducing unnecessary biopsies for melanoma.

Main Methods:

  • A prospective, multicenter, blinded study involving 1383 patients and 1831 pigmented skin lesions.
  • Diagnostic performance was assessed using the histologic reference standard.
  • A reader study evaluated 39 dermatologists' biopsy sensitivity to melanoma using standard images.

Main Results:

  • MelaFind achieved a sensitivity of 98.4% for melanoma detection (125/127 lesions).
  • MelaFind's specificity (9.9%) was superior to clinicians' (3.7%) for lesions biopsied to rule out melanoma (P=.02).
  • The system's biopsy ratio was 10.8:1, compared to an average dermatologist biopsy sensitivity of 78%.

Conclusions:

  • MelaFind is a safe and effective adjunct for evaluating pigmented skin lesions.
  • The system shows promise in improving early melanoma detection rates.
  • MelaFind can assist clinicians in identifying potentially malignant lesions more accurately.